Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development

2020 ◽  
Vol 29 (10) ◽  
pp. 1151-1162
Author(s):  
Milena Tocut ◽  
Yehuda Shoenfeld ◽  
Gisele Zandman-Goddard
2016 ◽  
Vol 25 (5) ◽  
pp. 573-583 ◽  
Author(s):  
Mariana Postal ◽  
Nailú Angélica Sinicato ◽  
Simone Appenzeller ◽  
Timothy B. Niewold

Healthcare ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 726
Author(s):  
Fulvia Ceccarelli ◽  
Venusia Covelli ◽  
Giulio Olivieri ◽  
Francesco Natalucci ◽  
Fabrizio Conti

Background: The COVID-19 pandemic contributes to the burden of living with different diseases, including Systemic Lupus Erythematosus (SLE). We described, from a narrative point of view, the experiences and perspectives of Italian SLE adults during the COVID-19 emergency, by distinguishing the illness experience before and after the lockdown. Methods: Fifteen patients were invited to participate. Illness narratives were collected between 22 and 29 March 2020 using a written modality to capture patients’ perspectives before and after the COVID-19 lockdown. We performed a two-fold analysis of collected data by distinguishing three narrative types and a qualitative analysis of content to identify the relevant themes and sub-themes reported. Results: Eight narratives included in the final analysis (mean length 436.9 words) have been written by eight females (mean age 43.3 ± 9.9 years, mean disease duration 13.1 ± 7.4 years). Six patients provided a quest narrative, one a chaos and the remaining one a restitution narrative. By text content analysis, we identified specific themes, temporally distinct before and after the lockdown. Before COVID-19, all the patients referred to a good control of disease, however the unexpected arrival of the COVID-19 emergency broke a balance, and patients perceived the loss of health status control, with anxiety and stress. Conclusions: We provided unique insight into the experiences of people with SLE at the time of COVID-19, underlining the perspective of patients in relation to the pandemic.


2021 ◽  
Vol 12 ◽  
Author(s):  
Chunjuan Yang ◽  
Jianmei Sun ◽  
Yipeng Tian ◽  
Haibo Li ◽  
Lili Zhang ◽  
...  

Systemic lupus erythematosus (SLE) is a common autoimmune connective tissue disease with unclear etiology and pathogenesis. Mesenchymal stem cell (MSC) and MSC derived extracellular vesicles (EVs) play important roles in regulating innate and adaptive immunity, which are involved in many physiological and pathological processes and contribute to the immune homeostasis in SLE. The effects of MSCs and EVs on SLE have been drawing more and more attention during the past few years. This article reviews the immunomodulatory effects and underlying mechanisms of MSC/MSC-EVs in SLE, which provides novel insight into understanding SLE pathogenesis and guiding the biological therapy.


2022 ◽  
Vol 7 (2) ◽  
pp. 90-92
Author(s):  
Shatavisa Mukherjee ◽  
Shambo S Samajdar ◽  
Kaushik Basu ◽  
Saibal Moitra ◽  
Santanu K Tripath

Drug induced lupus is an autoimmune condition secondary to drug exposure which leads to development of systemic lupus erythematosus (SLE). However, labelling the culprit drug needs a prudent insight into the pharmacological plausibility of each of the offending drugs in suspicion. Here we present a report where allergen immunotherapy was suspected to cause SLE and a deeper clinico-pharmacological evaluation cleared the air.


Cureus ◽  
2018 ◽  
Author(s):  
Gouthami Nalakonda ◽  
Mimsa Islam ◽  
Vera E Chukwu ◽  
Ahmad Soliman ◽  
Rujina Munim ◽  
...  

Lupus ◽  
2020 ◽  
Vol 29 (7) ◽  
pp. 791-794
Author(s):  
Gehan Elolemy ◽  
Abdulrahman Al Rashidi ◽  
Ahmed Dehrab ◽  
Ammar Almathkouri ◽  
Alex Varghese ◽  
...  

Lupus erythematosus profundus (LEP) is an unusual form of cutaneous lupus erythematosus (CLE) characterized by multiple subcutaneous induration and associated with considerable physical and psychological morbidity. The heterogeneity of CLE makes it difficult to understand its underlying pathogenesis and represents a therapeutic challenge. Recently, new insight into the pathogenesis of CLE has implicated various cytokines, opening doors to targeted biologic agents. We report a case of a 23-year-old female who presented with refractory LEP ulcers as an initial presentation of systemic lupus erythematosus. The lesions were resistant to multiple conventional therapies and remarkably responded to tocilizumab.


Sign in / Sign up

Export Citation Format

Share Document